Sangamo Therapeutics, Inc., a prominent biotechnology company operating within the Health Care sector, has been making significant strides in the field of genetic therapies. Based in Richmond, United States, the company is dedicated to developing innovative medications aimed at treating patients with genetic diseases. As of October 30, 2025, Sangamo Therapeutics is listed on the Nasdaq, with its shares trading at a close price of $0.6. This valuation reflects a notable fluctuation over the past year, with the company’s stock reaching a 52-week high of $3.18 on November 7, 2024, and a 52-week low of $0.41 on June 22, 2025.
The company’s market capitalization stands at approximately $180.42 million, indicating its current valuation in the biotechnology industry. Despite its promising advancements in genetic therapies, Sangamo Therapeutics has a price-to-earnings (P/E) ratio of -2.17, suggesting that the company is not currently generating profits. This negative P/E ratio is not uncommon in the biotechnology sector, where companies often invest heavily in research and development before achieving profitability.
Sangamo Therapeutics’ focus on genetic therapies positions it at the forefront of a rapidly evolving field. The company’s efforts are directed towards creating groundbreaking treatments that address the underlying genetic causes of diseases, offering hope to patients who have limited therapeutic options. By leveraging cutting-edge technology and scientific research, Sangamo Therapeutics aims to transform the landscape of genetic medicine.
As the company continues to expand its operations and pursue new therapeutic avenues, it remains committed to serving patients nationwide. The biotechnology sector’s dynamic nature presents both challenges and opportunities for Sangamo Therapeutics, as it navigates the complexities of drug development and regulatory approval processes. Nonetheless, the company’s dedication to innovation and patient care underscores its potential to make a lasting impact in the field of genetic therapies.
